ER-100 targets glaucoma and NAION through epigenetic reprogramming, with Phase II trials advancing, highlighting potential economic and healthcare disruptions in anti-aging therapies. Life Biosciences...
The FDA has greenlit the first human trial of ER-100, a partial epigenetic reprogramming therapy targeting age-related eye diseases, marking a pivotal step in anti-aging and regenerative medicine. A l...
